HealthifyMe
AI-driven nutrition and fitness coaching app now pivoting into GLP-1 clinical care.
On the record
Checkpoint: CEO's public target for US ARR to reach 'double-digit millions' from a $1-2M base
The call
HealthifyMe replaced most human coaches with AI to cut losses, and is now betting its future on GLP-1 partnerships while its India revenue keeps shrinking.
HealthifyMe helps people lose weight by logging food photos and chatting with AI coaches. The problem: big rivals like Noom already do this, and anyone with ChatGPT can replicate the core idea. HealthifyMe proved this themselves by replacing 600 human coaches with AI, which cut costs but also proved the service is easy to copy. The one thing that could matter is their new GLP-1 program, where they partner with Novo Nordisk to prescribe weight-loss drugs alongside coaching. That is harder to copy because it requires medical licenses and regulatory approval. But this new business is barely two years old and makes up less than 2% of revenue, so it has not proven itself yet. The real test comes in 2026: if their US business grows to tens of millions of dollars as promised, the medical angle might work. If not, they are mostly just another AI health app in a crowded field.
Why
01
AI pressure: OpenAI's GPT-Vision and voice models, which power HealthifyMe's own Ria/Ria Voice. Its food-photo tracking and chat coaching run on OpenAI's models, so any funded rival can rebuild the same tools. Could AI do the core job? Yes, likely.
02
Bigger players: Noom (already bundles GLP-1 drugs with coaching in the US) and drugmakers Novo Nordisk, Eli Lilly. Noom already sells GLP-1 plus coaching in the US, and Novo Nordisk and Eli Lilly control the drugs the whole model depends on. Could a giant copy it? Yes, easily.
03
What protects it. Its 100,000+ dish India food database and new Novo Nordisk tie-up take time to copy, but neither is locked in against a well-funded rival.
What would change this call
HealthifyMe's US ARR reaches or misses 'double-digit millions' by end-2026. Shows whether the GLP-1 coaching bundle is actually winning US customers.
India revenue figure for FY26 when reported. Shows whether the core India business keeps shrinking for a third straight year.
Any change or renegotiation in the Novo Nordisk India partnership terms. Shows whether the GLP-1 medical moat is stable or dependent on pharma goodwill.
India revenue figure for FY26 when reported. Shows whether the core India business keeps shrinking for a third straight year.
Any change or renegotiation in the Novo Nordisk India partnership terms. Shows whether the GLP-1 medical moat is stable or dependent on pharma goodwill.
Key numbers
- India revenue fell 14% YoY to Rs177cr in FY25
- Coaching staff cut from 1,000+ to 300-400
- US ARR only $1-2M as of Dec 2025
Named risks
- India core revenue has declined two straight years, FY23 to FY25, down 14% YoY in FY25.
- Core food-logging and chat coaching workflow is AI-replaceable, proven by company's own 70% coach cut.
- GLP-1 pivot depends on external pharma partner terms and India drug regulation.
- Coach turnover from automation reported to hurt user trust and retention.
- US ARR target of double-digit millions by end 2026 is a self-set, unproven milestone.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Noom | contesting | Launched Microdose GLP-1Rx bundling drugs, AI and coaching in the US, Nov 2025 |
| Cult.fit | gaining on | Larger, better-funded India wellness rival with new funding round reported Jan 2026 |
| FITTR | gaining on | Capital-efficient community coaching model cited as rising threat, Aug 2025 market research |
| Novo Nordisk and Eli Lilly | contesting | Control the GLP-1 molecule and pricing HealthifyMe's new model depends on, per Dec 2025 partnership |
Questions people ask
- Is HealthifyMe profitable in 2026?
- HealthifyMe's net loss narrowed from ₹88 crore in FY24 to ₹4 crore in FY25, but this came mainly from cutting coach headcount, not revenue growth. India revenue fell 14% YoY to ₹177 crore in FY25, as reported February 2026.
- Could AI replace HealthifyMe's human coaches?
- It already has: HealthifyMe cut human coaches from over 1,000 to 300-400 as its AI assistant Ria and voice tool Ria Voice, built on OpenAI, absorbed much of the coaching workload, per reporting dated February 2026.
- Who is HealthifyMe's biggest competitor?
- Noom already bundles GLP-1 prescriptions with AI coaching in the US, the exact market HealthifyMe is now targeting for growth, launching its Microdose GLP-1Rx Program in November 2025 ahead of HealthifyMe's own HealthifyRx push.
- Who owns HealthifyMe?
- HealthifyMe is privately held and VC-backed, founded in 2012 in Bangalore by Tushar Vashisht, Mathew Cherian and Sachin Shenoy. Investors include Khosla Ventures and LeapFrog Investments, which led a $20 million round closed in October 2024.
- Is HealthifyMe's US expansion succeeding?
- As of December 2025 the CEO said the US business ran at $1-2 million ARR, targeting 'double-digit millions' by end of 2026 and aiming for the US to become HealthifyMe's primary revenue source by 2027, a target not yet confirmed as met.
- What is HealthifyRx and is it working?
- HealthifyRx, launched April 2025, is a clinically supervised GLP-1 weight-loss program combining prescription drugs, AI, and human coaching. The CEO said in December 2025 it already makes up 'double-digit percentages' of revenue, alongside a new Novo Nordisk India partnership.
Timeline
- 2026-02-22Report shows FY25 India revenue fell 14% YoY to ₹177 crore
- 2025-12-03Novo Nordisk India partnership announced; Ria Voice AI coach launched
- 2025-04-30HealthifyRx GLP-1 clinical coaching program launched
- 2024-10Company rebranded from HealthifyMe to Healthify
- 2024-04-29Laid off about 150 employees, roughly 27% of workforce
- 2024-03-21Featured in OpenAI case study on GPT-Vision food tracking
- 2022-12-05Laid off about 150 employees, 15-20% of workforce
- 2021-02-16Set target of $400 million revenue run-rate by March 2025
Revision history
30 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Coaching built Healthify. Can GLP-1 drugs power its future? (2026-02-22)
- Healthify lays off 150 employees to make India business profitable (2024-04-29)
- HealthifyMe eyes $400 mln revenue run rate by Mar 2025 (2021-02-16)
- Healthify targets US market for growth and major source of revenue (2025-12-03)
- Healthify launches new weight loss program integrating GLP-1 therapy with lifestyle coaching (2025-04-30)
- 100 million Indians could be on GLP-1 drugs by 2030: Healthify CEO (2025-12-03)
- Saving lives with AI health coaching (2024-03-21)
- HealthifyMe Worth It in 2026? (2026-04-25)
- HealthifyMe Company Profile (2026-07-20)
- Valuation, Funding Rounds & Stock Price (2026-03-03)
- cbinsights.com (2026-07-30)
- HealthifyMe vs. Noom vs. MyFitnessPal (2025-08-22)